[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-atrial-appendage-closure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-atrial-appendage-closure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,52,75,99,121,152,175,197,230,260,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100619784","option-emea-clinical-trial-100619784",false,"NCT07349121","OPTION-EMEA Clinical Trial","Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]","OPTION-EMEA","Inclusion Criteria:\n\n1. Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN FLX™ Pro or WATCHMAN FLX™ for LAAC, per physician medical judgement and as per hospitals' standard of care.\n2. Subjects who are willing and able to provide informed consent.\n3. Subjects who are willing and able to participate in all testing associated with this clinical study at an approved investigational center.\n4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects who underwent prior AF ablation procedure.\n2. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes.\n3. Already surgically closed or otherwise excluded LAA.\n4. The LAA anatomy does not accommodate a Closure Device.\n5. Known or suspected atrial myxoma.\n6. Presence of intracardiac thrombus\\*.\n7. Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an atrial septal defect (ASD) \u002F patent foramen ovale (PFO) device.\n8. Subjects with a presence of a mechanical valve prosthesis in any position.\n9. Subjects with a myocardial infarction within 90 days prior to enrollment.\n10. Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within 90 days prior to enrollment.\n11. Any planned electrical cardioversion within 30 days following LAAC device implant.\n12. Subjects with a known inability to obtain vascular access.\n13. Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present.\n14. Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina).\n15. Subjects with any contraindications to short term use of anticoagulation therapy for conditions different from atrial fibrillation.\n16. Subjects who are pregnant or planning to be pregnant.\n17. Subjects with a life expectancy of ≤ 1 year per investigator's opinion.\n18. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.\n\nThe study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.",[27,28,29,30,31,32],"Atrial Fibrillation (AF)","Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Closure","Pulsed Field Ablation","Atrial Fibrillation Ablation Procedure","Concomitant Procedures",[34,35,36,37,38],"WATCHMAN","FARAPULSE","Concomitant","PFA","LAAC","RECRUITING","2026-06-26",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":43},"2026-06-18",{"date":47,"type":21},"2029-12",{"name":49,"class":50},"Boston Scientific Corporation","INDUSTRY",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100613105","watchman-flx-pro-european-registry-100613105","NCT07262255","WATCHMAN FLX Pro European Registry","Inclusion Criteria:\n\n1. Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.\n2. Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).\n3. Subject or legal representative who are willing and capable of providing informed consent.\n4. Subject is able and willing to return for required follow-up visits and examinations.\n5. Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subject has a documented life expectancy of less than 12 months.\n2. Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.\n3. Intracardiac thrombus is present.\n4. An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.\n5. The LAA anatomy will not accommodate a Closure Device.\n6. Subject has a known hypersensitivity or contraindications according to IFU.\n7. Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.",{"count":59,"type":21},1000,"12 Months","OBSERVATIONAL","The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.",[64,29],"Non-valvular Atrial Fibrillation (AF)",[38],"2026-06-23",{"date":68,"type":43},"2026-06-24",{"date":70,"type":43},"2025-12-17",{"date":72,"type":21},"2028-09",{"name":49,"class":50},14,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100538637","registry-on-luma-visions-verafeye-system-enlight-100538637","NCT06293430","Registry on Luma Vision's VERAFEYE System (ENLIgHT)","Registry on Luma Vision's VERAFEYE System in Catheter Ablation and Left Atrial Appendage Closure Procedures","ENLIgHT","Key Inclusion Criteria:\n\n* Subject is 18 years of age or of legal age to give informed consent specific to state and national law at the time of consent\n* Subjects is indicated for an atrial fibrillation ablation and\u002For a left atrial appendage closure procedure with the VERAFEYE System as navigation and imaging system, per physician discretion;\n* Subject is able to understand and willing to provide written informed consent\n* Subject is able and willing to complete all study assessments at an approved clinical investigational center\n\nKey Exclusion Criteria:\n\n* Subjects who have undergone a previous cardiac ablation for the treatment of PAF\u002FLAA Closure\n* Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion\n* Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)\n* Unrecovered\u002Funresolved Adverse Events from any previous invasive procedure\n* Subjects who are currently enrolled in another study (except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments)",{"count":84,"type":21},50,"The objective of the study is to compile real-world data on the use of the VERAFEYE System in standard of care atrial fibrillation (AF) ablation procedures and left atrial appendage closure (LAAC) procedures.",[87,29,88],"Atrial Fibrillation","Atrial Arrhythmia","NOT_YET_RECRUITING","2026-06-09",{"date":92,"type":43},"2026-06-10",{"date":94,"type":21},"2027-01-15",{"date":96,"type":21},"2027-09-15",{"name":98,"class":50},"LUMA Vision Ltd.",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":51},"100620732","agilis-rf-tsp-early-feasibility-study-100620732","NCT07361445","Agilis RF TSP Early Feasibility Study","Agilis Radiofrequency Transseptal System Early Feasibility Study","Inclusion Criteria:\n\n* Is able and willing to provide written informed consent prior to any clinical investigation-related procedure\n* Plans to undergo an ablation procedure in LA, LV or concomitant procedure with ablation and LAAO device implantation requiring transseptal puncture\n* Is at least 18 years of age\n* Able and willing to comply with all study requirements\n\nExclusion Criteria:\n\n* Currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from the study Sponsor\n* Pregnant or nursing\n* Known presence of intracardiac thrombus\n* Known existing circumferential pericardial effusion (\\>2 mm)\n* Previous interatrial septal patch or prosthetic atrial septal defect closure device\n* Any previous thromboembolic event with in the last 6 months\n* Known or suspected left atrial myxoma\n* Known or suspected myocardial infarction within the last two weeks\n* Unstable angina\n* Recent (within the last 3 months) cerebral vascular accident (CVA)\n* Patients with an active infection\n* Patients who do not tolerate anticoagulation therapy\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results",{"count":107,"type":21},60,[24],"This study is a prospective, acute, first-in-human, early feasibility study intended to assess the initial safety and performance of the Agilis™ Radiofrequency (RF) Transseptal (TSP) System in crossing the atrial septum for left atrial and left ventricular access during cardiac electrophysiology (EP) and interventional cardiology (IC) procedures. This study will be conducted in an acute setting. Subjects will be followed through hospital discharge, and no follow-up visits will be required for this study.",[111,29],"Cardiac Arrythmias","2026-05-29",{"date":114,"type":43},"2026-06-02",{"date":116,"type":43},"2026-02-16",{"date":118,"type":21},"2026-08-03",{"name":120,"class":50},"Abbott Medical Devices",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":151},"100639683","clot-less---closure-tailored-less-antithrombotic-strategy-after-laac-for-stroke-prevention-100639683","NCT07575867","CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention","CLOT-LESS","Inclusion Criteria:\n\n* Age ≥18 years;\n* Documented nonvalvular AF (≥30 seconds on ECG within previous 12 months);\n* CHA2DS2-VASc score ≥3 for women and ≥2 for men;\n* Signed informed consent to participate in the study;\n\nExclusion Criteria:\n\n* Active indication for anticoagulation OTHER than atrial fibrillation at the time of enrollment and\u002For the predicted\u002Funpredicted occurrence of such indications during the entire study period (e.g., mechanical valve, acute VTE, recent PE requiring \\>3 months anticoagulation);\n* Inability to tolerate at least 3 months of apixaban therapy (for LAAC arm);\n* Indications for antiplatelet therapy or therapy with P2Y12 inhibitors at the time of inclusion and\u002For the predicted\u002Funpredicted occurrence of such indications during the entire study period;\n* The presence of mechanical prosthetic heart valves, mitral stenosis of severe or moderate degree;\n* Active DVT requiring anticoagulation;\n* Congenital or acquired haemostasis disorders, rheumatic heart disease or recurrent deep vein thrombosis;\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%;\n* Glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin (stage IV or V chronic kidney disease) or dialysis patient;\n* Severe liver failure, including cirrhosis and Child-Pugh Class C\u002FD;\n* NYHA class IV congestive heart failure;\n* The patient had a myocardial infarction - MI with or without ST segment elevation (STEMI, NSTEMI) with or without intervention, within 30 days before LAAC;\n* The patient had a stroke (of any cause, ischemic or hemorrhagic) within 30 days before LAAC;\n* Intracardiac thrombus before LAAC;\n* Major bleeding according to BARC criteria (type 3 and higher) within 30 days before LAAC or before randomization;\n* Amyloid cardiomyopathy;\n* Platelet count \\\u003C 100,000 x 109\u002Fl;\n* The patient participates in another study, with the exception of observational studies without therapeutic interventions;\n* Pregnant or breast-feeding patients, patients planning pregnancy during the study period;\n* The LAAC procedure was unsuccessful or interrupted for technical reasons;\n* PDL (peridevice leak) ≥ 3 mm;\n* Contraindications for one of the treatment regimens prescribed by the study protocol (including allergic reactions);\n* Planned cardiac or non-cardiac surgical procedure within 30 days before or 90 days after LAAC. Minor procedures not requiring discontinuation of antithrombotic therapy are permitted (e.g., cardioversion, catheter ablation, cataract surgery);\n* The patient has a heart tumor, active infection, signs of physiological tamponade;\n* The documented life expectancy of the patient is less than 12 months;",{"count":129,"type":21},464,"This is a prospective, non-randomized, observational cohort study conducted at the FSBI \"NMRC TPM\" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.",[87,28,29,132,133,134,135],"Hemorrhage","Anticoagulants \u002F Administration & Dosage","Reduced-dose Apixaban","Thromboembolism",[137,138,139,140],"atrial fibrillation","left atrial appendage closure","anticoagulants","reduced dose apixaban","2026-05-04",{"date":143,"type":43},"2026-05-08",{"date":145,"type":21},"2026-04",{"date":147,"type":21},"2032-04",{"name":149,"class":150},"National Medical Research Center for Therapy and Preventive Medicine","OTHER_GOV",1,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":151},"100542863","intracardiac-versus-transesophageal-echocardiographic-guidance-for-left-atrial-appendage-occlusion-100542863","NCT06348394","Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion","ICETEE","Inclusion Criteria:\n\n1. Patients diagnosed for non-valvular atrial fibrillation with documented paroxysmal, persistent, or permanent NVAF.\n2. Deemed to be at high risk of stroke or systemic embolism (SE) defined as a CHADS2 score ≥2 or a CHA2DS2-VASc score ≥3.\n3. Patient suitable for OAC with warfarin or DOAC and have appropriate rationale to seek a nonpharmacologic alternative to long-term OAC, meeting commercial LAAO criteria indications.\n4. Can undergo appropriate pre-procedural imaging with Computed tomography (CT) or transesophageal echocardiography (TEE).\n5. Patient should be able to comply with the protocol.\n6. Provide written informed consent before study participation.\n7. Ages 18 and above\n\nExclusion Criteria\n\n1\\) A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:\n\n1. Presence of an intracardiac thrombus on the preprocedural TEE or CT.\n2. History of previously implanted device for atrial septal defect or patent foramen ovale.\n3. Severe LV dysfunction (LVEF \\\u003C 40%) or greater than moderate valvular heart disease.\n4. Enrollment in another study that competes or interferes with this study. Approval to dual enroll must be approved by the other study.\n5. Poor clinical condition like cardiogenic shock, which prohibits pre- and post-procedural function tests.\n6. Subject with planned cardiac intervention between the time of consenting and up to 60 days post-LAAO.\n7. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.\n8. For women of childbearing potential: Pregnant or breastfeeding women or planning pregnancy during the course of the investigation are excluded due to the risks involved in the procedure\n9. Children below 18 years, prisoners and patients who are unable to provide consent are excluded.","90 Years",{"count":161,"type":21},444,[24],"This single-center, prospective, randomized study will evaluate the safety and feasibility of Intracardiac echocardiography (ICE)-guided Left atrial appendage closure (LAAC) when compared to the traditional Transesophageal echocardiography (TEE) approach.",[29],"2026-04-13",{"date":167,"type":43},"2026-04-15",{"date":169,"type":43},"2025-02-25",{"date":171,"type":21},"2026-12-30",{"name":173,"class":174},"Baylor Research Institute","OTHER",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":184,"studyType":61,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100622341","preventing-neurologic-complications-in-valve-surgery-100622341","NCT07382362","Preventing Neurologic Complications in Valve Surgery","Strategies for the Prevention of Perioperative Neurological Complications in Cardiac Valve Surgery","Inclusion Criteria:\n\n* Adult patients (≥18 years) without atrial fibrillation who are scheduled to undergo open (direct-vision) surgical heart valve surgery and who are informed about the study and provide written informed consent to participate.\n\nExclusion Criteria:\n\n* History of prior cardiac surgery\n* history of cerebral infarction (ischemic stroke)\n* emergency surgery\n* infective endocarditis\n* pregnancy\n* refusal or inability to provide informed consent\u002Fdeclines participation in this study.",{"count":183,"type":21},100,"1 Year","In patients with valvular heart disease and atrial fibrillation (AF) undergoing surgical valve surgery, current guidelines recommend concomitant surgical management of the left atrial appendage (LAA) to prevent postoperative thromboembolic events, particularly neurologic embolic events. However, whether concomitant LAA management benefits patients without AF by reducing postoperative neurologic complications remains controversial.\n\nGiven these uncertainties, this study aims to evaluate whether concomitant LAA suture closure during surgical valve surgery is associated with a lower incidence of perioperative silent cerebral infarction.",[29],"2026-01-25",{"date":189,"type":43},"2026-02-02",{"date":191,"type":21},"2026-01-27",{"date":193,"type":21},"2028-07-31",{"name":195,"class":150},"China National Center for Cardiovascular Diseases",4,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":206,"studyType":61,"phases":4,"briefSummary":207,"conditions":208,"keywords":217,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":151},"100617119","cardiological-interventions-and-acute-stroke-treatment-study-100617119","NCT07314476","CardioLogical Interventions and Acute strOke Treatment sTudy","CLOT","Inclusion Criteria:\n\n* acute ischemic stroke in adult patient (18 years of age or older) as diagnosed according to the World Health Organization (WHO) criteria;\n* stroke with evidence of CT\u002FMRI DWI\u002FFLAIR acute lesion in the first neuroimaging or in the follow-up at 24-48 h;\n* interventional cardiological procedures performed within 28 days since the stroke onset (Percutaneuous Coronary Intervention - PCI, Transcatheter Aortic Valve Replacement - TAVR, Baloon Aortic Valvuloplasy - BAV, Percutaneous Mitral Valve Repair or Replacement, Patent Formaen Ovale - PFO - or Atrial Septal Defects - ASD - Closure, Left Atrial Appendage Closure, Transcatheter Pulmonary Valve Replacement, Percutaneous Closure of Paravalvular Leaks);\n* written informed consent provided by the patient himself or by proxy (for unconscious patients, cognitively impaired, or aphasic).\n\nExclusion Criteria:\n\n* Stroke-like symptoms due primarily to another non-ischemic\u002Fhemorrhagic acute neurological condition or stroke mimics (e.g. severe hypo- or hyperglycemia, migraine with aura, functional disorders, etc);\n* Spontaneous and post traumatic hemorrhagic stroke or spontaneous\u002Fpost-traumatic subarachnoid hemorrhage or subdural hematoma;\n* AciuImpossibility to achieve written informed consent",{"count":205,"type":21},400,"180 Days","The study aims to investigate characteristics and prognosis of ischemic stroke cases following cardiological interventions, focusing on the effectiveness and safety of acute ischemic stroke treatments.",[209,210,211,212,213,214,215,29,216],"Acute Ischemic Stroke AIS","Stroke Treatment","PCI Patients","Aortic Valve Replacement","Transcatheter Aortic Valve Replacement (TAVR)","Mitral Valve Repair","Mitral Valve Replacement","Transcatheter Pulmonary Valve Replacement (TPVR)",[218,219,220],"acute ischemic stroke","acute ischemic stroke treatments","cardiological intervention","2026-01-04",{"date":223,"type":43},"2026-01-07",{"date":225,"type":21},"2026-01",{"date":227,"type":21},"2028-12",{"name":229,"class":174},"University of L'Aquila",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100602584","phase-4-non-antithrombotic-versus-single-antiplatelet-therapy-following-left-atrial-appendage-closure-100602584","NCT07125417","Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","Non-Antithrombotic Versus. Single antiPlatelet Therapy Following Left Atrial Appendage Closure：NAPT-LAAC Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patient has documented non-valvular atrial fibrillation (i.e, atrial fibrillation without severe mitral stenosis or mechanical valves)\n2. Patient has CHA2DS2-VA score of 2 or greater\n3. Patient meets the guidelines for proper use of the left atrial appendage closure system including patient who has an increased risk of bleeding.\n4. Individual with nonvalvular atrial fibrillation who underwent successful LAAC (defined as no significant residual circumferential leak \\[\\>3 mm\\] or major morbidity by the time of procedure completion).\n5. Patient suitable for pharmacotherapy as defined in this study protocol in both NAPT and SAPT arms\n6. LAA anatomy is accommodate Boston Scientific WATCHMAN FLX Pro and LAAC procedure\n7. The patient and the investigator and\u002For subinvestigator agree that the patient will return for all required VISITs after LAAC procedure\n8. Patient has thoroughly understood the purpose of the study and has provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who are currently enrolled in other clinical trials, except when the patient is participating in a mandatory governmental registries or purely observational registries with no associated treatment.\n2. Individuals require long-term anticoagulation therapy for reasons other than atrial fibrillation (AF)-related stroke risk reduction (e.g.,thrombophilic conditions, previous pulmonary embolism, or deep venous thrombosis).\n3. Patients requiring oral antiplatelet therapy for reasons other than LAAC (e.g.,history of myocardial infarction, history of endovascular treatment, history of stroke\u002Ftransient ischemic attack, significant coronary stenosis proven by myocardial ischemia, severe carotid stenosis requiring invasive treatment,hematologic disease such as antiphospholipid syndrome or if the investigator and\u002For subinvestigator judged the need for antiplatelet therapy).\n4. Patients who meet one or more of the following criteria\n\n   * Patients who are contraindicated for DOAC or VKA\n   * Patients with a contraindication to aspirin\n   * Patients diagnosed with an allergy to aspirin\n5. Those who have or are scheduled to undergo cardiac or noncardiac intervention or surgery 45 days or 60 days before or after LAAC (e.g.,cardioversion, PCI, cardiac ablation, cataract surgery, other structural heart interventions).\n6. Patients with stroke (either ischemic or hemorrhagic) or transient ischemic attack within 30 days prior to enrollment\n7. Patients with active bleeding\n8. Individuals who lack LAA or whose LAA has been surgically ligated\n9. Individuals who experienced a myocardial infarction (with or without intervention) recorded as a non-ST elevation myocardial infarction or ST elevation myocardial infarction in the 30-day period prior to enrollment\n10. Patients with previous atrial septal repair or with atrial septal defect\u002Fpatent foramen ovale device\n11. Patients with mechanical valve prostheses at any site\n12. Persons with known contraindications to TEE\n13. Patients with active infection\n14. Individuals with NYHA class related IV congestive heart failure at enrollment\n15. Patients who are pregnant, breastfeeding, or wishing to become pregnant\n16. Patients with an expected life expectancy of less than 2 years\n17. Patients requiring emergency surgery for any reason\n18. Patients who, at the discretion of the investigator, have other medical, social, or psychological conditions that preclude adherence to appropriate consent or the follow-up tests required by the protocol\n19. Other patients whose investigator or subinvestigator judges their participation in the study to be inappropriate",{"count":20,"type":21},[239],"PHASE4","The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet Therapy (SAPT) with aspirin during the period from randomization to the end of observational period (4 years at the maximum) in non-valvular atrial fibrillation subjects with high bleeding risk.\n\nThe primary endpoint is a composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding from randomization to the end of study observation (up to a maximum follow-up of 4 years).\n\n* Participants will be enrolled in this study until the day following the implementation of LAAC and will be randomized to the SAPT arm and NAPT arm in a 1:1 ratio.\n* Participants will be observed for 4 years from the time the first subject is enrolled in this study.\n* Participants will visit the hospital at 45 days, 1 year, and 2 years after enrollment, and will also be followed up by telephone, basically at the end of the observation period (up to a maximum follow-up of 4 years).\n\n\\\u003CStudy treatment duration\\> In both arms, OAC monotherapy will be initiated in the first 24 hours of enrollment and continued for 45 days (allowed window period: plus 2 weeks)..\n\n* SAPT arm will continue to receive 45 days of OAC monotherapy followed by low-dose aspirin (75～100 mg\u002Fday) as an antithrombotic agent required through the end of the study observation period.\n* NAPT arm do not receive antithrombotic medication after 45 days of OAC monotherapy through the end of the study observation period.",[242,243,244,245,29],"Nonvalvular Atrial Fibrillation","Aspirin","Non-Antithrombotic Therapy","High Bleeding Risk",[29,247,248,243,249],"High bleeding risk","Non-Antithrombotic therapy","Nonvalvular Artial Fibrillation","2025-08-12",{"date":252,"type":43},"2025-08-15",{"date":254,"type":43},"2025-05-29",{"date":256,"type":21},"2030-03-31",{"name":258,"class":174},"OCEAN-SHD Study Group",21,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":151},"100582937","oral-anticoagulation-versus-left-atrial-appendage-occlusion-added-to-direct-oral-anticoagulation-in-patients-with-stroke-despite-oral-100582937","NCT06869811","Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral","Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral (ADD-LAAO TRIAL)","ADDLAAO","Inclusion Criteria:\n\n* Cardioembolic\\* Ischemic stroke despite OAC or DOAC within the last 6 months.\n* Documented AF (either valvular or non-valvular AF).\n* LAA suitable for closure (if LAA thrombus, just distal).\n* Functional status at inclusion with no severe disability (mRS\\\u003C4).\n* No contraindication for LAA assessment by CT or 3D-TEE.\n* \\>18 years\n* Life expectancy \\>1year\n* Able to understand written consent prior to the trial inclusion.\n* Able and willing to return for follow-up visits and tests.\n\nExclusion Criteria:\n\n* Absolute contraindication to OAC\u002FDOAC.\n* Non-compliance of OAC\u002FDOAC \\>24 hours within the last week before the index stroke (\\>1 dose per - - Antagonist Vit K and \\>2 doses per DOAC).\n* Lacunar Ischemic Stroke.\n* Symptomatic carotid disease (defined as \\> 50% lumen diameter narrowing on CTA, MRA, or TCD with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is \\\u003C 50% lumen diameter narrowing.\n* Planned cardiac intervention or surgery, which is invasive or requires sedation or anesthesia, within 3 months following randomization, other than study-related procedures such as LAAO and cardiac imaging (if applicable).\n* In the opinion of the investigator, is considered at high risk for general anesthesia and general anesthesia is planned for the study procedure.\n* Non-treated patent foramen ovale (PFO) or PFO closure device implanted.\n* Inferior vena cava filter.\n* Has any of the customary contraindications for a percutaneous catheterization procedure (e.g. subject is too small to accommodate the ICE probe (if planned) or required catheters, or subject has - active infection or bleeding disorder).\n* Customary contraindications for TEE\u002FTOE (e.g., presence of esophageal varices, esophageal stricture, or history of esophageal cancer).\n* Underwent catheter ablation for AF or atrial flutter within 60 days prior to randomization.\n* Experienced myocardial infarction within 90 days prior to randomization.\n* New York Heart Association Class IV Congestive Heart Failure.\n* Left ventricular ejection fraction ≤ 30% (per most recent assessment).\n* LAA is obliterated or surgically ligated.\n* Thrombocytopenia (defined as \\\u003C 50,000 platelets per microliter (\\\u003C50 x 109\u002FL) or anemia (defined as hemoglobin \\\u003C 10 g\u002FdL) requiring transfusions.\n* Hypersensitivity to any portion of the device material or individual components of the Amulet LAA occluder device (e.g., nickel allergy).\n* Allergy to contrast media if the patient needs angio-CT and cannot undergo TEE\u002FTOE.\n* Actively enrolled in, or plans to enroll in, a concurrent clinical study in which the active treatment arm may confound the results of this trial.\n* Is pregnant or breastfeeding, or pregnancy is planned during the course of the investigation.\n* Active endocarditis or other infection producing bacteremia.\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the Investigator's opinion, could limit the subject's ability to participate in clinical investigation or to comply with follow up requirements, or impact the scientific soundness of the clinical investigation results.","95 Years",{"count":270,"type":21},380,[24],"A total of 380 patients with ischemic stroke despite OAC will be included. Patients will be randomized 1:1 to the best medical treatment (control) or the combination of LAAO and DOAC or OAC. The study's primary endpoint will be the occurrence of a cardioembolic event (ischemic stroke or arterial peripheral embolism) within the first 12 months after inclusion.",[29],[275,276,277],"LAAO","Stroke","Oral Anticoagulation","2025-03-05",{"date":280,"type":43},"2025-03-11",{"date":282,"type":43},"2024-07-22",{"date":284,"type":21},"2027-07-22",{"name":286,"class":174},"Hospital Clinic of Barcelona",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":151},"100317171","austrian-left-atrial-appendage-closure-registry-100317171","NCT03409159","Austrian Left Atrial Appendage Closure Registry","Inclusion Criteria:\n\n* Patients who received LAAC in Austria\n\nExclusion Criteria:\n\n* Absence of informed consent",{"count":294,"type":21},200,"Left atrial appendage (LAA) occlusion (LAAC) has been introduced to treat patients with indication of oral anticoagulation (OAC) for atrial fibrillation (AF) with contraindication to OAC. This registry aims to document all LAAC procedures in Austria.",[87,29],"2024-11-19",{"date":299,"type":43},"2024-11-21",{"date":301,"type":43},"2017-05-16",{"date":303,"type":21},"2025-12",{"name":305,"class":174},"Medical University of Graz"]